Genovate Biotechnology Co Ltd (4130) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genovate Biotechnology Co Ltd (4130) has a cash flow conversion efficiency ratio of 0.012x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$16.93 Million ≈ $533.39K USD) by net assets (NT$1.38 Billion ≈ $43.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Genovate Biotechnology Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Genovate Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Genovate Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 4130 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Genovate Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genovate Biotechnology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MFS High Income Municipal Closed Fund
NYSE:CXE
|
0.024x |
|
Organic Tea Cosmetics Holdings Company Limited
KQ:900300
|
0.098x |
|
Sangsin Energy Display Precision Co.Ltd
KQ:091580
|
0.080x |
|
Gandhi Special Tubes Limited
NSE:GANDHITUBE
|
0.082x |
|
Afyon Cimento Sanayi TAS
IS:AFYON
|
0.110x |
|
Crest Ventures Limited
NSE:CREST
|
0.013x |
|
Mangata Holding S.A.
WAR:MGT
|
-0.002x |
|
e-Credible Co. Ltd
KQ:092130
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Genovate Biotechnology Co Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Genovate Biotechnology Co Ltd from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Genovate Biotechnology Co Ltd (4130) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.38 Billion ≈ $43.49 Million |
NT$43.79 Million ≈ $1.38 Million |
0.032x | -16.58% |
| 2024-12-31 | NT$1.45 Billion ≈ $45.66 Million |
NT$55.11 Million ≈ $1.74 Million |
0.038x | -34.11% |
| 2023-12-31 | NT$1.47 Billion ≈ $46.27 Million |
NT$84.78 Million ≈ $2.67 Million |
0.058x | +5293.20% |
| 2022-12-31 | NT$1.41 Billion ≈ $44.45 Million |
NT$1.51 Million ≈ $47.57K |
0.001x | +108.55% |
| 2021-12-31 | NT$1.38 Billion ≈ $43.44 Million |
NT$-17.26 Million ≈ $-543.75K |
-0.013x | -120.50% |
| 2020-12-31 | NT$1.43 Billion ≈ $44.93 Million |
NT$87.08 Million ≈ $2.74 Million |
0.061x | +93.55% |
| 2019-12-31 | NT$1.41 Billion ≈ $44.37 Million |
NT$44.43 Million ≈ $1.40 Million |
0.032x | -21.55% |
| 2018-12-31 | NT$1.56 Billion ≈ $49.26 Million |
NT$62.88 Million ≈ $1.98 Million |
0.040x | +105.73% |
| 2017-12-31 | NT$1.60 Billion ≈ $50.40 Million |
NT$31.27 Million ≈ $985.27K |
0.020x | -37.70% |
| 2016-12-31 | NT$2.25 Billion ≈ $70.86 Million |
NT$70.58 Million ≈ $2.22 Million |
0.031x | +104.92% |
| 2015-12-31 | NT$2.12 Billion ≈ $66.93 Million |
NT$32.53 Million ≈ $1.02 Million |
0.015x | -- |
About Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more